John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

An analysis by time since a patient's worsening heart failure (WHF) event showed that the efficacy of finerenone at reducing ...

Radiopharmaceuticals have been used to treat patients with prostate cancer for decades, but experts say there is more to ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Hence, the key product segments this market offers are drug-eluting stents, infusion pumps, transdermal patches, and inhalers ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs.

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination ...